NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN
20200345831 · 2020-11-05
Assignee
Inventors
Cpc classification
C12N2830/50
CHEMISTRY; METALLURGY
C12N7/00
CHEMISTRY; METALLURGY
A61K2039/64
HUMAN NECESSITIES
C12N2760/16134
CHEMISTRY; METALLURGY
A61P31/00
HUMAN NECESSITIES
A61K39/00
HUMAN NECESSITIES
Y02A50/30
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
C12N15/63
CHEMISTRY; METALLURGY
C12N2770/20034
CHEMISTRY; METALLURGY
C12N15/67
CHEMISTRY; METALLURGY
International classification
A61K39/00
HUMAN NECESSITIES
C12N15/63
CHEMISTRY; METALLURGY
C12N15/67
CHEMISTRY; METALLURGY
Abstract
The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
Claims
1. A composition comprising a mRNA encoding a coronaviruses spike (S) protein, said mRNA provided in complex with a lipid.
2. The composition of claim 1, wherein the mRNA comprises a Poly-A sequence.
3. The composition of claim 2, wherein the Poly-A sequence is about 25 to 400 adenosine nucleotides.
4. The composition of claim 1, wherein the mRNA comprises a histone stem loop sequence.
5. The composition of claim 1, wherein the mRNA comprises a 5 untranslated region (UTR) and/or a 3 UTR.
6. The composition of claim 5, wherein the mRNA comprises a 5 untranslated region (UTR) and a 3 UTR.
7. The composition of claim 1, wherein the coronaviruses S protein is from a Severe Acute Respiratory Syndrome (SARS) coronavirus.
8. The composition of claim 1, wherein the lipid comprises a cationic lipid.
9. The composition of claim 1, wherein the coding sequence of the mRNA has a G/C content that is increased compared with the G/C content of the coding sequence of the wild-type RNA.
10. The composition of claim 1, wherein the mRNA comprises a nucleotide analog substitution.
11. The composition of claim 1, wherein the mRNA comprises a methylated 5 cap.
12. The composition of claim 10, wherein the nucleotide analog substation comprises at least one pseudouridine-5-triphosphate substitution.
13. The composition of claim 1, further comprising a polyethyleneglycol.
14. The composition of claim 1, further comprising an adjuvant.
15. The composition of claim 1, wherein the mRNA comprises a methylated 5 cap; a 5 UTR; a 3 UTR and a Poly-A sequence of about 25 to 400 adenosine nucleotides.
16. The composition of claim 15, wherein the mRNA has a G/C content that is increased compared with the G/C content of the coding sequence of the wild-type RNA.
17. A method of stimulating an immune response in a subject comprising administering an effective amount a composition according to claim 1 to the subject.
18. The method of claim 17, wherein the composition is administered by intradermal or intramuscular injection.
19. A method of stimulating an immune response in a subject comprising administering an effective amount a composition according to claim 16 to the subject.
20. The method of claim 19, wherein the composition is administered by intradermal or intramuscular injection.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0229] The following Figures are intended to illustrate the invention further and shall not be construed to limit the present invention thereto.
[0230]
[0231]
[0232]
[0233]
[0234]
[0235]
[0249]
[0251]
[0253]
[0255]
[0257]
[0259]
[0260]
[0262]
[0264]
[0266]
[0268]
[0270]
[0272]
[0273]
[0274]
[0276]
[0278]
[0280]
[0282]
EXAMPLES
[0284] The following Examples are intended to illustrate the invention further and shall not be construed to limit the present invention thereto.
1. Generation of Histone-Stem-Loop Consensus Sequences
[0285] Prior to the experiments, histone stem-loop consensus sequences were determined on the basis of metazoan and protozoan histone stem-loop sequences. Sequences were taken from the supplement provided by Lopez et al. (Dvila Lpez, M., & Samuelsson, T. (2008), RNA (New York, N.Y.), 14(1), 1-10. doi:10.1261/rna.782308), who identified a large number of natural histone stem-loop sequences by searching genomic sequences and expressed sequence tags. First, all sequences from metazoa and protozoa (4001 sequences), or all sequences from protozoa (131 sequences) or alternatively from metazoa (3870 sequences), or from vertebrates (1333 sequences) or from humans (84 sequences) were grouped and aligned. Then, the quantity of the occurring nucleotides was determined for every position. Based on the tables thus obtained, consensus sequences for the 5 different groups of sequences were generated representing all nucleotides present in the sequences analyzed. In addition, more restrictive consensus sequences were also obtained, increasingly emphasizing conserved nucleotides
2. Preparation of DNA-Templates
[0286] A vector for in vitro transcription was constructed containing a T7 promoter followed by a GC-enriched sequence coding for Photinus pyralis luciferase (ppLuc(GC)), the center part of the 3 untranslated region (UTR) of alpha-globin (ag), and a poly(A) sequence. The poly(A) sequence was immediately followed by a restriction site used for linearization of the vector before in vitro transcription in order to obtain mRNA ending in an A64 poly(A) sequence. mRNA obtained from this vector accordingly by in vitro transcription is designated as ppLuc(GC)-ag-A64. [0287] Linearization of this vector at alternative restriction sites before in vitro transcription allowed to obtain mRNA either extended by additional nucleotides 3 of A64 or lacking A64. In addition, the original vector was modified to include alternative sequences. In summary, the following mRNAs were obtained from these vectors by in vitro transcription (mRNA sequences are given in
TABLE-US-00016 ppLuc(GC) ag (SEQ ID NO: 43) ppLuc(GC) ag A64 (SEQ ID NO: 44) ppLuc(GC) ag histoneSL (SEQ ID NO: 45) ppLuc(GC) ag A64 histoneSL (SEQ ID NO: 46) ppLuc(GC) ag A120 (SEQ ID NO: 47) ppLuc(GC) ag A64 ag (SEQ ID NO: 48) ppLuc(GC) ag A64 aCPSL (SEQ ID NO: 49) ppLuc(GC) ag A64 PolioCL (SEQ ID NO: 50) ppLuc(GC) ag A64 G30 (SEQ ID NO: 51) ppLuc(GC) ag A64 U30 (SEQ ID NO: 52) ppLuc(GC) ag A64 SL (SEQ ID NO: 53) ppLuc(GC) ag A64 N32 (SEQ ID NO: 54) [0288] Furthermore DNA plasmid sequences coding for the pathogenic antigen HA (H1N1/PR8) was prepared accordingly as described above. [0289] In summary, the following mRNAs were obtained from these vectors by in vitro transcription (mRNA sequences are given in
3. In Vitro Transcription
[0292] The DNA-template according to Example 2 was linearized and transcribed in vitro using T7-Polymerase. The DNA-template was then digested by DNase-treatment. All mRNA-transcripts contained a 5-CAP structure obtained by adding an excess of N7-Methyl-Guanosine-5-Triphosphate-5-Guanosine to the transcription reaction. mRNA thus obtained was purified and resuspended in water.
4. Enzymatic Adenylation of mRNA [0293] Two mRNAs were enzymatically adenylated: [0294] ppLuc(GC)-ag-A64 and ppLuc(GC)-ag-histoneSL. [0295] To this end, RNA was incubated with E. coli Poly(A)-polymerase and ATP (Poly(A) Polymerase Tailing Kit, Epicentre, Madison, USA) following the manufacturer's instructions. mRNA with extended poly(A) sequence was purified and resuspended in water. The length of the poly(A) sequence was determined via agarose gel electrophoresis. Starting mRNAs were extended by approximately 250 adenylates, the mRNAs obtained are designated as ppLuc(GC)-ag-A300 and ppLuc(GC)-ag-histoneSL-A250, respectively.
5. Luciferase Expression by mRNA Electroporation [0296] HeLa cells were trypsinized and washed in opti-MEM. 110.sup.5 cells in 200 l of opti-MEM each were electroporated with 0.5 g of ppLuc-encoding mRNA. As a control, mRNA not coding for ppLuc was electroporated separately. Electroporated cells were seeded in 24-well plates in 1 ml of RPMI 1640 medium. 6, 24, or 48 hours after transfection, medium was aspirated and cells were lysed in 200 l of lysis buffer (25 mM Tris, pH 7.5 (HCl), 2 mM EDTA, 10% glycerol, 1% Triton X-100, 2 mM DTT, 1 mM PMSF). Lysates were stored at 20 C. until ppLuc activity was measured.
6. Luciferase Expression by mRNA Lipofection [0297] HeLa cells were seeded in 96 well plates at a density of 210.sup.4 cells per well. The following day, cells were washed in opti-MEM and then transfected with 0.25 g of Lipofectin-complexed ppLuc-encoding mRNA in 150 l of opti-MEM. As a control, mRNA not coding for ppLuc was lipofected separately. In some wells, opti-MEM was aspirated and cells were lysed in 200 l of lysis buffer 6 hours after the start of transfection. In the remaining wells, opti-MEM was exchanged for RPMI 1640 medium at that time. In these wells, medium was aspirated and cells were lysed in 200 l of lysis buffer 24 or 48 hours after the start of transfection. Lysates were stored at 20 C. until ppLuc activity was measured.
7. Luciferase Measurement
[0298] ppLuc activity was measured as relative light units (RLU) in a BioTek SynergyHT plate reader at 5 seconds measuring time using 50 l of lysate and 200 l of luciferin buffer (25 mM Glycylglycin, pH 7.8 (NaOH), 15 mM MgSO.sub.4, 2 mM ATP, 75 M luciferin). Specific RLU were calculated by subtracting RLU of the control RNA from total RLU.
8. Luciferase Expression by Intradermal mRNA Injection (Luciferase Expression In Vivo) [0299] Mice were anaesthetized with a mixture of Rompun and Ketavet. Each ppLuc-encoding mRNA was injected intradermally (0.5 g of mRNA in 50 l per injection). As a control, mRNA not coding for ppLuc was injected separately. 16 hours after injection, mice were sacrificed and tissue collected. Tissue samples were flash frozen in liquid nitrogen and lysed in a tissue lyser (Qiagen) in 800 l of lysis buffer (25 mM Tris, pH 7.5 (HCl), 2 mM EDTA, 10% glycerol, 1% Triton X-100, 2 mM DTT, 1 mM PMSF). Subsequently samples were centrifuged at 13500 rpm at 4 C. for 10 minutes. Lysates were stored at 80 C. until ppLuc activity was measured (see 7. luciferase measurement).
9. Detection of an Antigen-Specific B-Cell Immune Response (Antibodies)
[0300] BALB/c mice (8 mice per group) were vaccinated twice within 7 days intradermally with the vaccine comprising 10 g mRNA coding for HA (Hemagglutinin of A/Puerto Rico/8/34, according to SEQ ID NO. 55 and 56). For negative control, mice were treated with buffer. Detection of an antigen specific immune response was carried out by detecting HA protein specific antibodies. Therefore, blood samples were taken from vaccinated mice four weeks after the last vaccination and sera were prepared. MaxiSorp plates (Nalgene Nunc International) were coated with HA protein (Charles River Laboratories). After blocking with 1PBS containing 0.05% Tween-20 and 1% BSA the plates were incubated with diluted mouse serum (1:50). Subsequently a biotin-coupled secondary antibody (Anti-mouse-IgG Dianova, cat. #115035003) was added. After washing, the plate was incubated with Horseradish peroxidase-streptavidin and subsequently the conversion of the ABTS substrate (2,2-azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid) was measured. Results of this experiment are shown in
10. Detection of an Antigen-Specific Cellular Immune Response (T Cell Immune Response) by ELISPOT:
[0301] C57BL/6 mice are vaccinated intradermally with HA encoding mRNA (Hemagglutinin of A/Puerto Rico/8/34, according to SEQ ID NO. 55 and 56). complexed with protamine (2 times in 7 days). Control mice are treated with buffer. 1 week after the last vaccination mice are sacrificed, the spleens are removed and the splenocytes are isolated. The splenocytes are restimulated for 7 days in the presence of peptides from the above antigen (peptide library) or coincubated with dendritic cells generated from bone marrow cells of native syngeneic mice, which are electroporated with mRNA coding for the antigen. To determine an antigen-specific cellular immune response INFgamma secretion was measured after re-stimulation. For detection of INFgamma a coat multiscreen plate (Millipore) is incubated overnight with coating buffer 0.1 M carbonate-bicarbonate buffer pH 9.6, 10.59 g/l Na2CO3, 8.4 g/l NaHCO.sub.3) comprising antibody against INF (BD Pharmingen, Heidelberg, Germany). Stimulators and effector cells are incubated together in the plate in the ratio of 1:20 for 24 h. The plate is washed with 1PBS and incubated with a biotin-coupled secondary antibody. After washing with 1PBS/0.05% Tween-20 the substrate (5-Bromo-4-Cloro-3-Indolyl Phosphate/Nitro Blue Tetrazolium Liquid Substrate System from Sigma Aldrich, Taufkirchen, Germany) is added to the plate and the conversion of the substrate could be detected visually.
11. Results
11.1 Histone Stem-Loop Sequences:
[0302] In order to characterize histone stem-loop sequences, sequences from metazoa and protozoa (4001 sequences), or from protozoa (131 sequences) or alternatively from metazoa (3870 sequences), or from vertebrates (1333 sequences) or from humans (84 sequences) were grouped and aligned. Then, the quantity of the occurring nucleotides was determined for every position. Based on the tables thus obtained, consensus sequences for the 5 different groups of sequences were generated representing all nucleotides present in the sequences analyzed. Within the consensus sequence of metazoa and protozoa combined, 3 nucleotides are conserved, a T/U in the loop and a G and a C in the stem, forming a base pair. Structurally, typically a 6 base-pair stem and a loop of 4 nucleotides is formed. However, deviating structures are common: Of 84 human histone stem-loops, two contain a stem of only 5 nucleotides comprising 4 base-pairs and one mismatch. Another human histone stem-loop contains a stem of only 5 base-pairs. Four more human histone stem-loops contain a 6 nucleotide long stem, but include one mismatch at three different positions, respectively. Furthermore, four human histone stem-loops contain one wobble base-pair at two different positions, respectively. Concerning the loop, a length of 4 nucleotides seems not to be strictly required, as a loop of 5 nucleotides has been identified in D. discoideum. [0303] In addition to the consensus sequences representing all nucleotides present in the sequences analyzed, more restrictive consensus sequences were also obtained, increasingly emphasizing conserved nucleotides. In summary, the following sequences were obtained: [0304] (Cons): represents all nucleotides present [0305] (99%): represents at least 99% of all nucleotides present [0306] (95%): represents at least 95% of all nucleotides present [0307] (90%): represents at least 90% of all nucleotides present [0308] The results of the analysis of histone stem-loop sequences are summarized in the following Tables 1 to 5 (see also
TABLE-US-00017 TABLE 1 Metazoan and protozoan histone stem-loop consensus sequence: (based on an alignment of 4001 metazoan and protozoan histone stem-loop sequences) (see also FIG. 1) < < < < < < .Math. .Math. .Math. # A 2224 1586 3075 2872 1284 184 0 13 12 9 1 47 59 0 # T 172 188 47 205 19 6 0 569 1620 199 3947 3830 3704 4001 # C 1557 2211 875 918 2675 270 0 3394 2342 3783 51 119 227 0 # G 25 16 4 6 23 3541 4001 25 27 10 2 5 11 0 Cons N* N* N N N N G N N N N N N T 99% H* H* H H V V G Y Y Y Y H H T 95% M* H* M H M S G Y Y Y T T Y T 90% M* M* M M M S G Y Y C T T T T .Math. > > > > > > # A 675 3818 195 1596 523 0 14 3727 61 771 2012 2499 # T 182 1 21 15 11 0 179 8 64 557 201 690 # C 3140 7 50 31 16 4001 3543 154 3870 2636 1744 674 # G 4 175 3735 2359 3451 0 265 112 4 37 43 138 Cons N N N N N C N N N N* N* N* 99% H R V V R C B V H H* N* N* 95% M A R R R C S M C H* H* H* 90% M A G R R C S A C H* M* H*
TABLE-US-00018 TABLE 2 Protozoan histone stem-loop consensus sequence: (based on an alignment of 131 protozoan histone stem-loop sequences) (see also FIG. 2) < < < < < < .Math. .Math. .Math. .Math. > > > > > > # A 52 32 71 82 76 13 0 12 12 9 1 46 3 0 75 82 53 79 20 0 4 94 17 35 74 56 # T 20 32 37 21 8 3 0 21 85 58 86 70 65 131 28 1 17 13 10 0 15 7 31 32 20 28 # C 45 59 20 25 38 0 0 86 8 54 42 13 58 0 27 2 6 31 10 131 112 5 82 58 30 40 # G 14 8 3 3 9 115 131 12 26 10 2 2 5 0 1 46 55 8 91 0 0 25 1 6 7 7 Cons N* N* N N N D G N N N N N N T N N N N N C H N N N* N* N* 99% N* N* N N N D G N N N B N N T H V N N N C H N H N* N* N* 95% N* N* H H N R G N N N Y H B T H R D N N C Y D H H* N* N* 90% N* H* H H V R G N D B Y H Y T H R D H N C Y R H H* H* H*
TABLE-US-00019 TABLE 3 Metazoan histone stem-loop consensus sequence: (based on an alignment of 3870 (including 1333 vertebrate sequences) metazoan histone stem-loop sequences) (see also FIG. 3) < < < < < < .Math. .Math. .Math. # A 2172 1554 3004 2790 1208 171 0 1 0 0 0 1 56 0 # T 152 156 10 184 11 3 0 548 1535 141 3861 3760 3639 3870 # C 1512 2152 855 893 2637 270 0 3308 2334 3729 9 106 169 0 # G 11 8 1 3 14 3426 3870 13 1 0 0 3 6 0 Cons N* N* N N N N G N B Y Y N N T 99% H* H* M H M V G Y Y Y T Y H T 95% M* M* M M M S G Y Y C T T Y T 90% M* M* M M M S G Y Y C T T T T .Math. > > > > > > # A 600 3736 142 1517 503 0 10 3633 44 736 1938 2443 # T 154 0 4 2 1 0 164 1 33 525 181 662 # C 3113 5 44 0 6 3870 3431 149 3788 2578 1714 634 # G 3 129 3680 2351 3360 0 265 87 3 31 36 131 Cons N V N D N C N N N N* N* N* 99% H R V R R C B V M H* H* N* 95% M A G R R C S M C H* H* H* 90% M A G R R C S A C H* M* H*
TABLE-US-00020 TABLE 4 Vertebrate histone stem-loop consensus sequence: (based on an alignment of 1333 vertebrate histone stem-loop sequences) (see also FIG. 4) < < < < < < .Math. .Math. .Math. # A 661 146 1315 1323 920 8 0 1 0 0 0 1 4 0 # T 63 121 2 2 6 2 0 39 1217 2 1331 1329 1207 1333 # C 601 1062 16 6 403 1 0 1293 116 1331 2 0 121 0 # G 8 4 0 2 4 1322 1333 0 0 0 0 3 1 0 Cons N* N* H N N N G H Y Y Y D N T 99% H* H* M A M G G Y Y C T T Y T 95% H* H* A A M G G C Y C T T Y T 90% M* M* A A M G G C T C T T T T .Math. > > > > > > # A 441 1333 0 1199 21 0 1 1126 26 81 380 960 # T 30 0 1 0 1 0 2 1 22 91 91 12 # C 862 0 2 0 0 1333 1328 128 1284 1143 834 361 # G 0 0 1330 134 1311 0 2 78 1 18 28 0 Cons H A B R D C N N N N* N* H* 99% H A G R R C C V H N* N* M* 95% M A G R G C C V C H* H* M* 90% M A G R G C C M C Y* M* M*
TABLE-US-00021 TABLE 5 Homo sapiens histone stem-loop consensus sequence: (based on an alignment of 84 human histone stem-loop sequences) (see also FIG. 5) < < < < < < .Math. .Math. .Math. .Math. > > > > > > # A 10 17 84 84 76 1 0 1 0 0 0 1 0 0 12 84 0 65 3 0 0 69 5 0 10 64 # T 8 6 0 0 2 2 0 1 67 0 84 80 81 84 5 0 0 0 0 0 0 0 4 25 24 3 # C 62 61 0 0 6 0 0 82 17 84 0 0 3 0 67 0 1 0 0 84 84 5 75 57 44 17 # G 4 0 0 0 0 81 84 0 0 0 0 3 0 0 0 0 83 19 81 0 0 10 0 2 6 0 Cons N* H* A A H D G H Y C T D Y T H A S R R C C V H B* N* H* 99% N* H* A A H D G H Y C T D Y T H A S R R C C V H B* N* H* 95% H* H* A A M G G C Y C T T T T H A G R G C C V M Y* N* M* 90% H* M* A A A G G C Y C T T T T M A G R G C C R M Y* H* M* [0309] Wherein the used abbreviations were defined as followed:
TABLE-US-00022 abbreviation Nucleotide bases remark G G Guanine A A Adenine T T Thymine U U Uracile C C Cytosine R G or A Purine Y T/U or C Pyrimidine M A or C Amino K G or T/U Keto S G or C Strong (3H bonds) W A or T/U Weak (2H bonds) H A or C or T/U Not G B G or T/U or C Not A V G or C or A Not T/U D G or A or T/U Not C N G or C or T/U or A Any base * present or not Base may be present or not
11.2 the Combination of Poly(A) and histoneSL Increases Protein Expression from mRNA in a Synergistic Manner. [0310] To investigate the effect of the combination of poly(A) and histoneSL on protein expression from mRNA, mRNAs with different sequences 3 of the alpha-globin 3-UTR were synthesized: mRNAs either ended just 3 of the 3-UTR, thus lacking both poly(A) sequence and histoneSL, or contained either an A64 poly(A) sequence or a histoneSL instead, or both A64 poly(A) and histoneSL 3 of the 3-UTR. Luciferase-encoding mRNAs or control mRNA were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after transfection (see following Table 6 and
TABLE-US-00023 TABLE 6 RLU at RLU at RLU at mRNA 6 hours 24 hours 48 hours ppLuc(GC)-ag-A64-histoneSL 466553 375169 70735 ppLuc(GC)-ag-histoneSL 50947 3022 84 ppLuc(GC)-ag-A64 10471 19529 4364 ppLuc(GC)-ag 997 217 42 [0311] Little luciferase was expressed from mRNA having neither poly(A) sequence nor histoneSL. Both a poly(A) sequence or the histoneSL increased the luciferase level to a similar extent. Either mRNA gave rise to a luciferase level much higher than did mRNA lacking both poly(A) and histoneSL. Strikingly however, the combination of poly(A) and histoneSL further strongly increased the luciferase level, manifold above the level observed with either of the individual elements. The magnitude of the rise in luciferase level due to combining poly(A) and histoneSL in the same mRNA demonstrates that they are acting synergistically. [0312] The synergy between poly(A) and histoneSL was quantified by dividing the signal from poly(A)-histoneSL mRNA (+/+) by the sum of the signals from histoneSL mRNA (/+) plus poly(A) mRNA (+/) (see following Table 7).
TABLE-US-00024 TABLE 7 RLU at RLU at RLU at A64 histoneSL 6 hours 24 hours 48 hours + + 466553 375169 70735 + 50947 3022 84 + 10471 19529 4364 Synergy 7.6 16.6 15.9 [0313] The factor thus calculated specifies how much higher the luciferase level from mRNA combining poly(A) and histoneSL is than would be expected if the effects of poly(A) and histoneSL were purely additive. The luciferase level from mRNA combining poly(A) and histoneSL was up to 16.6 times higher than if their effects were purely additive. This result confirms that the combination of poly(A) and histoneSL effects a markedly synergistic increase in protein expression.
11.3 the Combination of Poly(A) and histoneSL Increases Protein Expression from mRNA Irrespective of their Order. [0314] The effect of the combination of poly(A) and histoneSL might depend on the length of the poly(A) sequence and the order of poly(A) and histoneSL. Thus, mRNAs with increasing poly(A) sequence length and mRNA with poly(A) and histoneSL in reversed order were synthesized: Two mRNAs contained 3 of the 3-UTR either an A120 or an A300 poly(A) sequence. One further mRNA contained 3 of the 3-UTR first a histoneSL followed by an A250 poly(A) sequence. Luciferase-encoding mRNAs or control mRNA were lipofected into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after the start of transfection (see following Table 8 and
TABLE-US-00025 TABLE 8 RLU at RLU at RLU at mRNA 6 hours 24 hours 48 hours ppLuc(GC)-ag-histoneSL-A250 98472 734222 146479 ppLuc(GC)-ag-A64-histoneSL 123674 317343 89579 ppLuc(GC)-ag-histoneSL 7291 4565 916 ppLuc(GC)-ag-A300 4357 38560 11829 ppLuc(GC)-ag-A120 4371 45929 10142 ppLuc(GC)-ag-A64 1928 26781 537 [0315] Both an A64 poly(A) sequence or the histoneSL gave rise to comparable luciferase levels. In agreement with the previous experiment did the combination of A64 and histoneSL strongly increase the luciferase level, manifold above the level observed with either of the individual elements. The magnitude of the rise in luciferase level due to combining poly(A) and histoneSL in the same mRNA demonstrates that they are acting synergistically. The synergy between A64 and histoneSL was quantified as before based on the luciferase levels of A64-histoneSL, A64, and histoneSL mRNA (see following Table 9). The luciferase level from mRNA combining A64 and histoneSL was up to 61.7 times higher than if the effects of poly(A) and histoneSL were purely additive.
TABLE-US-00026 TABLE 9 RLU at RLU at RLU at A64 histoneSL 6 hours 24 hours 48 hours + + 123674 317343 89579 + 7291 4565 916 + 1928 26781 537 Synergy 13.4 10.1 61.7 [0316] In contrast, increasing the length of the poly(A) sequence from A64 to A120 or to A300 increased the luciferase level only moderately (see Table 8 and
TABLE-US-00027 TABLE 10 RLU at RLU at RLU at histoneSL A250/A300 6 hours 24 hours 48 hours + + 98472 734222 146479 + 7291 4565 916 + 4357 38560 11829 Synergy 8.5 17.0 11.5 [0317] In summary, a highly synergistic effect of the combination of histoneSL and poly(A) on protein expression from mRNA has been demonstrated for substantially different lengths of poly(A) and irrespective of the order of poly(A) and histoneSL.
11.4 the Rise in Protein Expression by the Combination of Poly(A) and histoneSL is Specific [0318] To investigate whether the effect of the combination of poly(A) and histoneSL on protein expression from mRNA is specific, mRNAs with alternative sequences in combination with poly(A) were synthesized: These mRNAs contained 3 of A64 one of seven distinct sequences, respectively. Luciferase-encoding mRNAs or control mRNA were electroporated into HeLa cells. Luciferase levels were measured at 6, 24, and 48 hours after transfection (see following Table 11 and
TABLE-US-00028 TABLE 11 RLU at RLU at RLU at mRNA 6 hours 24 hours 48 hours ppLuc(GC)-ag-A64-N32 33501 38979 2641 ppLuc(GC)-ag-A64-SL 28176 20364 874 ppLuc(GC)-ag-A64-U30 41632 54676 3408 ppLuc(GC)-ag-A64-G30 46763 49210 3382 ppLuc(GC)-ag-A64-PolioCL 46428 26090 1655 ppLuc(GC)-ag-A64-aCPSL 34176 53090 3338 ppLuc(GC)-ag-A64-ag 18534 18194 989 ppLuc(GC)-ag-A64-histoneSL 282677 437543 69292 ppLuc(GC)-ag-histoneSL 27597 3171 0 ppLuc(GC)-ag-A64 14339 48414 9357 [0319] Both a poly(A) sequence or the histoneSL gave rise to comparable luciferase levels. Again, the combination of poly(A) and histoneSL strongly increased the luciferase level, manifold above the level observed with either of the individual elements, thus acting synergistically. In contrast, combining poly(A) with any of the alternative sequences was without effect on the luciferase level compared to mRNA containing only a poly(A) sequence. Thus, the combination of poly(A) and histoneSL increases protein expression from mRNA in a synergistic manner, and this effect is specific.
11.5 the Combination of Poly(A) and histoneSL Increases Protein Expression from mRNA in a Synergistic Manner In Vivo. [0320] To investigate the effect of the combination of poly(A) and histoneSL on protein expression from mRNA in vivo, Luciferase-encoding mRNAs with different sequences 3 of the alpha-globin 3-UTR or control mRNA were injected intradermally into mice: mRNAs contained either an A64 poly(A) sequence or a histoneSL instead, or both A64 poly(A) and histoneSL 3 of the 3-UTR.
[0321] Luciferase levels were measured at 16 hours after injection (see following Table 12 and
TABLE-US-00029 TABLE 12 RLU at mRNA 16 hours ppLuc(GC)-ag-A64-histoneSL 38081 ppLuc(GC)-ag-histoneSL 137 ppLuc(GC)-ag-A64 4607 [0322] Luciferase was expressed from mRNA having either a histoneSL or a poly(A) sequence. Strikingly however, the combination of poly(A) and histoneSL further strongly increased the luciferase level, manifold above the level observed with either of the individual elements. The magnitude of the rise in luciferase level due to combining poly(A) and histoneSL in the same mRNA demonstrates that they are acting synergistically. [0323] The synergy between poly(A) and histoneSL was quantified by dividing the signal from poly(A)-histoneSL mRNA (+/+) by the sum of the signals from histoneSL mRNA (/+) plus poly(A) mRNA (+/) (see following Table 13).
TABLE-US-00030 TABLE 13 RLU at A64 histoneSL 16 hours + + 38081 + 137 + 4607 Synergy 8.0 [0324] The factor thus calculated specifies how much higher the luciferase level from mRNA combining poly(A) and histoneSL is than would be expected if the effects of poly(A) and histoneSL were purely additive. The luciferase level from mRNA combining poly(A) and histoneSL was 8 times higher than if their effects were purely additive. This result confirms that the combination of poly(A) and histoneSL effects a markedly synergistic increase in protein expression in vivo.
11.6 the Combination of Poly(A) and histoneSL Increases the Level of Antibodies Elicited by Vaccination with mRNA. [0325] To investigate the effect of the combination of poly(A) and histoneSL on the induction of antibodies elicited by vaccination with mRNA, Balb/c mice were vaccinated intradermally with, HA-encoding mRNAs with different sequences 3 of the mutated alpha-globin 3-UTR. mRNAs contained either an A64 poly(A) sequence or both A64 poly(A) and histoneSL 3 of the 3-UTR. The level of HA-specific antibodies in vaccinated and control mice was analyzed by ELISA with serial dilutions of sera (see